{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:26:05Z","timestamp":1786983965152,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.acra.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T16:27:22Z","timestamp":1637771242000},"page":"1308-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET\/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-1207","authenticated-orcid":false,"given":"Hwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Eads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina M.","family":"Aparici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pryma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2021.10.004_bib0001","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.23883","article-title":"Neuroendocrine tumor epidemiology: contrasting Norway and North America","volume":"113","author":"Hauso","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.acra.2021.10.004_bib0002","unstructured":"Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system: World Health Organization; 2010."},{"key":"10.1016\/j.acra.2021.10.004_bib0003","unstructured":"Osamura R, Grossman A, Korbonits M, et al. WHO classification of tumours of endocrine organs. IARC Lyon, France; 2017."},{"key":"10.1016\/j.acra.2021.10.004_bib0004","series-title":"WHO Classification of Tumours Editorial Board; Digestive system tumours, WHO classification of tumours","year":"2019"},{"key":"10.1016\/j.acra.2021.10.004_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.acra.2021.10.004_bib0006","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.acra.2021.10.004_bib0007","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.acra.2021.10.004_bib0008","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.acra.2021.10.004_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000445165","article-title":"The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories","volume":"104","author":"Milione","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.acra.2021.10.004_bib0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MPA.0000000000000735","article-title":"Treatment Response and outcomes of Grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated","volume":"46","author":"Raj","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.acra.2021.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.acra.2021.10.004_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acra.2021.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/MPA.0000000000001693","article-title":"Concordance between the Ki-67 index cutoff value of 55% and differentiation in neuroendocrine tumor and neuroendocrine carcinoma in grade 3 pancreatic neuroendocrine neoplasms","volume":"49","author":"Shi","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.acra.2021.10.004_bib0014","first-page":"346","article-title":"The diagnosis and treatment of pancreatic NEN-G3\u2014a focus on clinicopathological difference of NET-G3 and NEC G3","volume":"3","author":"Hijioka","year":"2018","journal-title":"JOP S"},{"key":"10.1016\/j.acra.2021.10.004_bib0015","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm8071032","article-title":"Role of combined [(68)Ga]Ga-DOTA-SST analogues and [(18)F]FDG PET\/CT in the management of GEP-NENs: a systematic review","volume":"8","author":"Carideo","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0016","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.diii.2020.06.006","article-title":"Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma","volume":"101","author":"Azoulay","year":"2020","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.acra.2021.10.004_bib0017","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.acra.2019.06.012","article-title":"Differential diagnosis of nonhypervascular pancreatic neuroendocrine neoplasms from pancreatic ductal adenocarcinomas, based on computed tomography radiological features and texture analysis","volume":"27","author":"Yu","year":"2020","journal-title":"Acad Radiol"},{"key":"10.1016\/j.acra.2021.10.004_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2340389","article-title":"Clinical and prognostic value of PET\/CT imaging with combination of (68)Ga-DOTATATE and (18)F-FDG in gastroenteropancreatic neuroendocrine neoplasms","volume":"2018","author":"Zhang","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.acra.2021.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","article-title":"Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement","volume":"21","author":"Coriat","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.acra.2021.10.004_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/wjnm.WJNM_67_20","volume":"20","author":"Loharkar","year":"2021","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0022","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/MNM.0000000000001072","article-title":"Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?","volume":"40","author":"Basu","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.acra.2021.10.004_bib0023","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.acra.2021.10.004_bib0024","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2967\/jnumed.120.257659","article-title":"Dual positron emission tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarker","volume":"62","author":"Chan","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0019-5154.198047","article-title":"Biostatistics series module 7: the statistics of diagnostic tests","volume":"62","author":"Hazra","year":"2017","journal-title":"Indian J Dermatol."},{"key":"10.1016\/j.acra.2021.10.004_bib0026","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1017\/S1481803500007764","article-title":"Diagnostic testing: an emergency medicine perspective","volume":"4","author":"Worster","year":"2002","journal-title":"Cjem"},{"key":"10.1016\/j.acra.2021.10.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3762651","article-title":"Defining an optimal cut-point value in ROC analysis: an alternative approach","volume":"2017","author":"Unal","year":"2017","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/926295","article-title":"Peptide receptor targeting in cancer: the somatostatin paradigm","volume":"2013","author":"Barbieri","year":"2013","journal-title":"Int J Pept"},{"key":"10.1016\/j.acra.2021.10.004_bib0029","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000330616","article-title":"Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors","volume":"95","author":"Schmid","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.acra.2021.10.004_bib0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1871520616666161031143301","article-title":"The Warburg effect and the hallmarks of cancer","volume":"17","author":"Schwartz","year":"2017","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.acra.2021.10.004_bib0031","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/MNM.0000000000000522","article-title":"Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET\/CT on the basis of volumetric parameters in neuroendocrine tumors","volume":"37","author":"Abdulrezzak","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.acra.2021.10.004_bib0032","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00259-014-2850-3","article-title":"Comparison of the prognostic values of 68Ga-DOTANOC PET\/CT and 18F-FDG PET\/CT in patients with well-differentiated neuroendocrine tumor","volume":"41","author":"Sharma","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.acra.2021.10.004_bib0033","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","author":"Kratochwil","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.acra.2021.10.004_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2020-0165","article-title":"(68) Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.acra.2021.10.004_bib0035","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acra.2021.10.004_bib0036","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2967\/jnumed.119.241414","article-title":"Prognostic value of (18)F-FDG PET\/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy","volume":"61","author":"Zhang","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors","volume":"58","author":"Panagiotidis","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.acra.2021.10.004_bib0038","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1159\/000439434","article-title":"Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor","volume":"103","author":"Grillo","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.acra.2021.10.004_bib0039","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1007\/s11605-020-04651-1","article-title":"The role of Ki-67 index cut-off of 55% and differentiation in redefining NET and NEC for grade 3 gastrointestinal neuroendocrine neoplasms","volume":"24","author":"Shi","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.acra.2021.10.004_bib0040","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin Ultrasound CT MR"},{"key":"10.1016\/j.acra.2021.10.004_bib0041","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.acra.2020.08.028","article-title":"68Ga-DOTATATE PET\/CT: the optimum Standardized Uptake Value (SUV) internal reference","volume":"29","author":"Ragab","year":"2022","journal-title":"Acad Radiol"},{"key":"10.1016\/j.acra.2021.10.004_bib0042","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2017.07.041","article-title":"Interlaboratory variability of Ki67 staining in breast cancer","volume":"84","author":"Focke","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acra.2021.10.004_bib0043","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ejso.2014.06.016","article-title":"Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease","volume":"40","author":"Singh","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.acra.2021.10.004_bib0044","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.acra.2021.10.004_bib0045","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.acra.2021.05.017","article-title":"Preoperative prediction of G1 and G2\/3 grades in patients with nonfunctional pancreatic neuroendocrine tumors using multimodality imaging","volume":"29","author":"Liu","year":"2022","journal-title":"Acad Radiol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633221004621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633221004621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:55:16Z","timestamp":1761036916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633221004621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1076633221004621"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2021.10.004","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET\/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}